Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3

Ever since direct-acting antiviral agents (DAA) have been approved and released into the world, numerous studies on the efficacy, adverse effects and drug-drug interactions of interferon-free DAA combination therapy have been studied and published. With all oral DAA therapy showing sustained virolog...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Korean journal of gastroenterology Jg. 67; H. 3; S. 132 - 136
1. Verfasser: Jung, Young Kul
Format: Journal Article
Sprache:Koreanisch
Veröffentlicht: Korea (South) 01.03.2016
Schlagworte:
Antiviral Agents - therapeutic use
Drug Therapy, Combination
Genotype
Hepacivirus - genetics
Hepacivirus - isolation & purification
Hepatitis C - drug therapy
Hepatitis C - virology
Humans
Interferon-alpha - therapeutic use
Practice Guidelines as Topic
Republic of Korea
Ribavirin - therapeutic use
Sofosbuvir - therapeutic use
Antiviral agents
Genotype
Chronic hepatitis C
Evidence-based medicine
ISSN:1598-9992, 2233-6869
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Ever since direct-acting antiviral agents (DAA) have been approved and released into the world, numerous studies on the efficacy, adverse effects and drug-drug interactions of interferon-free DAA combination therapy have been studied and published. With all oral DAA therapy showing sustained virological response rate of 80-90% with minimal adverse events, HCV eradication has now become a realistic goal. DAA combination treatments were approved and adapted to practice in Korea in 2015, and Korean Association for the Study of the Liver (KASL) has revised the guideline based on the systematic approach that reflects evidence-based medicine and expert opinions. In this article, new recommendations for treatment of chronic HCV genotype 2 and 3 infected patients will be introduced base on KASL practice guidelines for management of hepatitis C that has been updated in 2015.
Bibliographie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1598-9992
2233-6869
DOI:10.4166/kjg.2016.67.3.132